Related Experiment Video
Updated: Oct 4, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
[Risk of hypertension after heart transplantation in the follow-up period]
K Wierzbicki1, M Garlicki, P Przybyłowski
1Klinika Chirirgii Serca i Naczyń, Instytutu Kardiologii, Collegium Medicum, Uniwersytetu Jagielońsklego w Krakowie.
Insights
Hypertension is common after heart transplantation (HTX). Factors like age, male sex, and kidney issues increase risk, while calcium channel blockers may be effective treatments.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Context:
- Orthotopic heart transplantation (HTX) is a life-saving procedure.
- Post-transplant hypertension (HTN) is a significant complication affecting long-term outcomes.
- Understanding HTN risk factors and effective management is crucial for heart transplant recipients.
Purpose:
- To analyze the incidence and risk factors of hypertension in heart transplant recipients.
- To evaluate the effectiveness of pharmacotherapy in managing post-transplant hypertension.
- To identify predictors of uncontrolled hypertension after HTX.
Summary:
- 65% of 220 heart transplant recipients developed hypertension (HTN).
- Older age, male sex, and ischemic cardiomyopathy increased HTN risk.
- Calcium channel blockers were associated with better blood pressure control, while kidney insufficiency correlated with higher HTN severity.
Impact:
- Identifies key risk factors for post-heart transplant hypertension.
- Suggests calcium channel blockers may be particularly effective for managing HTN in this population.
- Highlights the link between kidney function and hypertension control after HTX.
Abstract:
From October 1988 to March 2000, 58 patients underwent orthotopic heart transplantation (HTX). Data of 220 heart recipients with the follow up > or = 3 months after HTX were analyzed using the average values of blood pressure measured with the sphigmo-manometer. 65% of patients were diagnosed with the hypertension (HA). 39.9% of those patients (NTA group) had the systolic blood pressure < or = 140 mmHg and diastolic blood pressure < or = 90 mmHg during pharmacotherapy. 60.1% of hypertensive patients (NTB group) had the systolic pressure > 140 mmHg and/or diastolic pressure > 90 mmHg despite pharmacotherapy. 35% of all patients had normal blood pressure after HTX (HNA group). Patients with hypertension were older and the end stage ischemic cardiomyopathy was more frequently indication for HTX. Significantly more females were in NTA group. We observed no influence of the daily dose of cyclosporine or other immunosuppressive drugs on HA. The average blood concentration of cyclosporine A and mycophenolate mofetil was similar in all groups. The calcium channel blockers and inhibitors of angiotensin converting enzyme were main tool of pharmacotherapy used. In NTA group calcium channels blockers were used more frequently. In NTB group there was a statistically significant higher blood level of creatinine. After HTX there is a high risk of HA, which: increases with age, with the ischemic cardiomyopathy as indication to HTX, is significantly higher in males, there is no correlation between HA and the dosage and blood level of cyclosporine, increases with kidney insufficiency. In monotherapy calcium channel blockers seem to be especially effective.
Related Concept Videos
Kidney Transplant III: Nursing Management
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Hypertension V: Nursing Management
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension and Regulation of Blood Pressure
